Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Acticor Biotech | October 05, 2020

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke. This Dose Escalation Phase was successfully completed with 60 patients enrolled from 6 European countries (France, Belgium, Germany, Spain, Switzerland and Italy). 5 cohorts of patients presenting with an acute ischemic stroke episode of moderate to severe intensity were enrolled in this study and randomly received glenzocimab at one of 4 ascending doses or a placebo, in a blind fashion as a 6-hour single-dose infusion. Patients were evaluated continuously for 24 hours, then 7 and 90 days after the episode. Approximately 50% were also treated with the thrombolytic agent rtPA (ACTILYSE®), and the other 50% received rtPA and underwent a mechanical thrombectomy. The DSMB met on 5 occasions in between each cohort and at the end of the last administration, and they analyzed the safety data with a particular focus on the advent of intra-cerebral hemorrhages and other bleeding related events. The last analysis performed after the target dose of 1000mg had been administered to 12 patients confirmed both the absence of increased bleeding when glenzocimab is added to rtPA and to rtPA and thrombectomy, and the absence of any dose-related trend in the number and nature of adverse events recorded.

Spotlight

For biopharmaceutical and biotechnology companies, innovation is imperative. Economic growth in these industries relies heavily upon investment in product development—perhaps more so than any other industry

Spotlight

For biopharmaceutical and biotechnology companies, innovation is imperative. Economic growth in these industries relies heavily upon investment in product development—perhaps more so than any other industry

Related News

INDUSTRIAL IMPACT

Resilience Partners with a Major Pharmaceutical Company for Strategic Biomanufacturing

Resilience | February 20, 2023

National Resilience, Inc. (Resilience), a manufacturing company with a technology-focused mission to improve access to complex medications, recently announced a 10-year biomanufacturing partnership with a top pharmaceutical company for its portfolio of services in process and analytical development, drug substance manufacturing, and drug product manufacturing. The extensive agreement covers prospective biologic, vaccine, nucleic acid, cell, and gene therapy manufacturing. Resilience’s recently acquired facility in Cincinnati, Ohio, is its worldwide center of excellence to produce commercial medicinal products, and will deliver the first product as stipulated under the agreement. The development of complicated pharmaceuticals, such as cell and gene therapies, has not kept up with the rate of scientific advancements that are supporting them. Resilience brings together exceptional minds in science and engineering to bridge this gap with access to state-of-the-art technology. Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience, said, “The partnership announced today is a major milestone for Resilience.” He further added, “We are grateful to have this opportunity to work with our partner to deliver important, life-saving medicines to patients. We understand the trust placed with us to manufacture the medicine with the highest quality, regulatory compliance, and reliability. We are committed to maintaining a responsible manufacturing operation that exceeds the expectations of our partners and enables us to make a meaningful impact on global healthcare.” (Source – Business Wire) With the addition of this alliance to its expanding commercial portfolio, the company anticipates generating record revenues in 2023. About Resilience Resilience is a technology-focused biomanufacturing startup. The company intends to increase access to sophisticated medications. The firm is establishing a long-term network of cutting-edge, all-inclusive manufacturing solutions to guarantee that the therapies of today and the future may be produced efficiently, securely, and at scale. Resilience aims to continuously develop the science of biopharmaceutical manufacture and development, so their partners concentrate on the discoveries that enhance patients' lives and safeguard biopharmaceutical supply chains from future disruptions.

Read More

MEDTECH, INDUSTRIAL IMPACT

Atreca and Xencor Launch New Program to Develop T Cell Engaging Bispecific Antibody

Atreca, Inc. | February 07, 2023

On February 6, 2023, Atreca, Inc. (Atreca), a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics, and Xencor, Inc., a clinical-stage biopharmaceutical company that develops cytokines and engineered antibodies for the treatment of autoimmune diseases and cancer, announced, as part of their existing strategic collaboration, that they have mutually selected the first program combining an Atreca-discovered antibody with Xencor's XmAb® bispecific Fc domain and a cytotoxic T-cell binding domain (CD3). The initiative announced is the first of up to two collaborative programs that can be selected by mutual agreement for future development and commercialization, with each partner sharing 50% of expenses and earnings. This program's clinical development, regulatory, and commercialization operations will be led by Atreca, while Xencor will lead the second prospective joint program. Furthermore, the agreement permits each partner to pursue up to two collaborative programs separately. The unveiled joint program is based on APN-346958, an antibody discovered by Atreca. APN-346958 targets a new RNA-binding protein and is tumor-reactive in at least 50% of samples for six tumor types tested: thyroid, colorectal, head and neck, melanoma, urothelial, and brain cancer. In preclinical tests, the XmAb bispecific antibodies engineered against the target of APN-346958 displayed substantial anti-tumor activity. Atreca and Xencor hope to name a candidate from the program later this year, with Atreca aiming for an investigational new drug (IND) application in early 2025. About Atreca Founded in 2011, Atreca is a biopharmaceutical firm that employs its distinct discovery platform to create innovative antibody-based immunotherapeutics. Its Immune Repertoire CaptureT​M (IRCTM) technology provides unmatched insight into how cancer patients' immune responses can lead to improved clinical outcomes offering access to an undiscovered terrain in oncology. Atreca was created by industry leaders, scientists, and investors who believe that unlocking today's patients' immune responses is the key to developing a new generation of therapies.

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Aldevron Launches Type-V CRISPR Nuclease, Eureca-V™ MAD7®

Aldevron | January 20, 2023

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, diagnostic, and agricultural workflows. In addition, a pass-through license for research use is conveyed with the purchase of Eureca-V nuclease, allowing customers to thoroughly examine the product without committing to a long-term licensing agreement. Vice President and General Manager of Aldevron's Protein Business Unit, Tom Foti, said, "The availability of Eureca-V drives forward the entire genomics medicine industry and enhances Aldevron's position as a supplier of choice for CRISPR drug substances and drug products." He added, "We are proud to work alongside our partners at Inscripta to bring the innovative, off-the-shelf catalog product to market now as well as provide a clear path to GMP in 2023." (Source – Cision PR Newswire) Eureca-V at the research grade level ensures the acceleration of CRISPR translational research. In addition, the product will assist academic and commercial scientists seeking a wild-type Type-V CRISPR nuclease that targets T-rich regions of the genome. Venkata Indurthi, Chief Scientific Officer at Aldevron, expressed, "We are thrilled to offer Eureca-V product at research grade starting today, and later this year, our clients can expect a smooth transition to our GMP product." He further added, "Aldevron's extensive history in CRISPR nucleases allows researchers to develop therapies that will eventually address global health issues." (Source – Cision PR Newswire) It will be the third GMP CRISPR nuclease by Aldevron and the first Type-V nuclease available as a GMP catalog product. It is a leader in supplying vital raw materials and reagents used for cell and gene therapy manufacturing. The company's portfolio of CRISPR nucleases is applied globally in preclinical and clinical research applications. About Aldevron Aldevron is a pioneer in advancing biological science. Its custom development and manufacturing services have provided scientists all across the world with the components they need to accelerate research and create labs for revolutionary science and breakthrough discoveries. The company aims to deliver products and services that contribute significantly to global biological research. It seeks to be the partner of choice forproducing high-quality plasmid DNA, proteins, enzymes, and other biologicals to support its clients' goals.

Read More